Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase.
Pigment epithelium-derived factor (PEDF), a potent blocker of angiogenesis in vivo, and of endothelial cell migration and tubule formation, binds with high affinity to an as yet unknown protein on the surfaces of endothelial cells. Given that protein fingerprinting suggested a match of a approximately 60 kDa PEDF-binding protein in bovine retina with Bos taurus F(1)-ATP synthase beta-subunit, and that F(1)F(o)-ATP synthase components have been identified recently as cell-surface receptors, we examined the direct binding of PEDF to F(1). Size-exclusion ultrafiltration assays showed that recombinant human PEDF formed a complex with recombinant yeast F(1). Real-time binding as determined by surface plasmon resonance demonstrated that yeast F(1) interacted specifically and reversibly with human PEDF. Kinetic evaluations revealed high binding affinity for PEDF, in agreement with PEDF affinities for endothelial cell surfaces. PEDF blocked interactions between F(1) and angiostatin, another antiangiogenic factor, suggesting overlapping PEDF-binding and angiostatin-binding sites on F(1). Surfaces of endothelial cells exhibited affinity for PEDF-binding proteins of approximately 60 kDa. Antibodies to F(1)beta-subunit specifically captured PEDF-binding components in endothelial plasma membranes. The extracellular ATP synthesis activity of endothelial cells was examined in the presence of PEDF. PEDF significantly reduced the amount of extracellular ATP produced by endothelial cells, in agreement with direct interactions between cell-surface ATP synthase and PEDF. In addition to demonstrating that PEDF binds to cell-surface F(1), these results show that PEDF is a ligand for endothelial cell-surface F(1)F(o)-ATP synthase. They suggest that PEDF-mediated inhibition of ATP synthase may form part of the biochemical mechanisms by which PEDF exerts its antiangiogenic activity.
Notari
Luigi
L
Section of Protein Structure and Function, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, NIH, Bethesda, MD, USA.
Arakaki
Naokatu
N
Mueller
David
D
Meier
Scott
S
Amaral
Juan
J
Becerra
S P
SP
D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000818:Animals; D001667:Binding, Competitive; D002417:Cattle; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000378:metabolism; D005136:Eye Proteins / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D009414:Nerve Growth Factors / Q000378:metabolism*; D011485:Protein Binding; D021122:Protein Subunits / Q000378:metabolism; D006180:Proton-Translocating ATPases / Q000378:metabolism*; D012441:Saccharomyces cerevisiae / Q000201:enzymology*; D015843:Serpins / Q000378:metabolism*; D020349:Surface Plasmon Resonance; D000099174:Pigment Epithelium-Derived Factor
D000255:Adenosine Triphosphate; D005136:Eye Proteins; D009414:Nerve Growth Factors; D021122:Protein Subunits; D006180:Proton-Translocating ATPases; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor
J Biol Chem. 2005 Jan 21;280(3):1740-5
15528193
Protein Expr Purif. 2004 Oct;37(2):479-85
15358374
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2736-47
16043845
Cancer Res. 2005 Jun 15;65(12):5144-52
15958558
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2593-7
11226284
J Biol Chem. 2006 Dec 8;281(49):38022-37
17032652
J Biol Chem. 2002 Nov 22;277(47):45400-7
12237317
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2811-6
10077593
J Cell Biochem. 2005 Oct 1;96(2):242-61
16094651
Trends Mol Med. 2006 Oct;12(10):497-502
16962374
Diabetes. 2001 Dec;50(12):2641-5
11723044
Trends Mol Med. 2002 Jul;8(7):330-4
12114112
Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3287-93
11726635
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1318-26
19850839
Protein Sci. 1996 Dec;5(12):2575-82
8976566
J Cell Physiol. 2001 Aug;188(2):253-63
11424092
J Cell Sci. 2001 Dec;114(Pt 24):4421-8
11792807
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13632-7
17698806
J Neurosci. 2002 Nov 1;22(21):9378-86
12417663
Curr Opin Lipidol. 2006 Jun;17(3):279-84
16680033
Biochem Biophys Res Commun. 2004 Sep 3;321(4):788-94
15358096
Anticancer Res. 2000 Sep-Oct;20(5A):2923-30
11062702
J Mol Cell Cardiol. 2004 Aug;37(2):497-506
15276019
J Biol Chem. 1999 Oct 29;274(44):31605-12
10531367
Nat Med. 2003 Jun;9(6):774-80
12740569
Neurobiol Dis. 1999 Dec;6(6):523-32
10600408
Exp Eye Res. 2006 May;82(5):739-40
16364294
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6656-61
11381144
Prog Retin Eye Res. 2004 Sep;23(5):561-77
15302351
Cancer Res. 2004 May 15;64(10):3679-86
15150128
Biochemistry. 1998 Jul 28;37(30):10643-52
9692954
Invest Ophthalmol Vis Sci. 1996 Sep;37(10):1984-93
8814138
Protein Expr Purif. 1995 Aug;6(4):447-56
8527930
Invest Ophthalmol Vis Sci. 2002 May;43(5):1574-80
11980876
Mol Ther. 2003 Jul;8(1):72-9
12842430
Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1994-2000
12037010
Mol Cancer Res. 2003 Nov;1(13):931-9
14638865
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4497-504
14507898
Science. 1999 Jul 9;285(5425):245-8
10398599
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8909-14
12072560
Cancer Res. 2006 Jan 15;66(2):875-82
16424020